Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Albuterol
Drug ID BADD_D00056
Description Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.[Label,A174379,A174400]
Indications and Usage Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.[Label,F3265,F3268]
Marketing Status approved; vet_approved
ATC Code R03CC02; R03AC02
DrugBank ID DB01001
KEGG ID D02147
MeSH ID D000420
PubChem ID 2083
TTD Drug ID D0K5CB
NDC Product Code 69543-291; 64980-442; 71205-899; 69238-1345; 70710-1062; 59651-333; 70771-1511; 71205-898; 59651-334; 63629-2611; 64980-443; 69238-1344; 70710-1061; 70771-1512; 69543-290
UNII QF8SVZ843E
Synonyms Albuterol | Salbutamol | 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol | Ventolin | Sultanol | Albuterol Sulfate | Proventil
Chemical Information
Molecular Formula C13H21NO3
CAS Registry Number 18559-94-9
SMILES CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Concomitant disease aggravated08.01.03.0630.000006%-
Munchausen's syndrome19.24.02.0010.000011%-
Normal newborn18.08.06.0010.000015%-
Live birth18.08.02.0070.000027%-
Biliary dyskinesia09.03.02.0040.000006%-
Negative thoughts19.15.02.0120.000006%-
Sputum retention22.02.03.0120.000006%-
Asthmatic crisis22.03.01.0180.000039%-
Diastolic hypotension24.06.03.0120.000006%-
Stress cardiomyopathy02.04.01.012; 24.04.04.0260.000061%-
Psychological trauma19.01.02.0170.000008%-
Neuromyotonia10.04.05.008; 15.05.03.033; 16.32.01.008; 17.05.03.0160.000008%-
Acute haemorrhagic oedema of infancy01.01.04.011; 10.02.02.029; 23.06.02.010; 24.12.04.0010.000008%-
Anisocoria06.05.03.013; 17.02.11.0090.000024%-
Diaphragmatic rupture12.01.18.002; 22.09.02.0070.000006%-
Drug effect less than expected08.06.01.0360.000028%-
Drug ineffective for unapproved indication08.06.01.038; 12.09.02.0020.000030%-
Factitious disorder19.24.02.0020.000014%-
Illness08.01.03.0910.000092%-
Intermenstrual bleeding21.01.01.0150.000008%-
Near death experience17.02.04.023; 19.10.05.0070.000011%-
Prolonged expiration22.02.01.0400.000006%-
Reaction to excipient10.01.01.0420.000012%-
Sleep disorder due to a general medical condition19.02.04.0030.000025%-
Superficial vein thrombosis24.01.02.0160.000006%-
Swelling of eyelid06.04.04.018; 10.01.05.026; 23.04.01.0260.000006%-
Taste disorder07.14.03.004; 17.02.07.0290.000031%-
Therapeutic product effect decreased08.06.01.0500.000324%-
Therapeutic product effect delayed08.06.01.0510.000087%-
Therapeutic product effect incomplete08.06.01.0520.000232%-
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene